Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;26(1):15-16.
doi: 10.1016/S1470-2045(24)00685-5. Epub 2024 Nov 29.

Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus

Vincent J Cogliano  1 , Emanuela Corsini  1 , Agnès Fournier  1 , Heather H Nelson  1 , Consolato M Sergi  1 , Alexandra M M Antunes  1 , Elizabeth K Cahoon  1 , Guosheng Chen  1 , Talita Duarte-Salles  1 , Eric Engels  1 , Jingqi Fu  1 , Dori Germolec  1 , Reza Ghiasvand  1 , Blánaid Hicks  1 , Bertrand J Jean-Claude  1 , Gopabandhu Jena  1 , Catharina M Lerche  1 , Xilin Li  1 , Angela Lupattelli  1 , Thomas P Ong  1 , Libia Vega  1 , Diana R Withrow  1 , Alistair B A Boxall  1 , Lamia Benbrahim-Tallaa  1 , Aline de Conti  1 , Andrew Kunzmann  1 , Elisa Pasqual  1 , Roland Wedekind  1 , Xiaobei Deng  1 , Yahya Mahamat-Saleh  1 , Azam Majidi  1 , Laia Peruchet-Noray  1 , Julia Rezende Da Silva  1 , Eero Suonio  1 , Susana Viegas  1 , Yue Zhai  1 , Heidi Mattock  1 , Caterina Facchin  1 , Mary K Schubauer-Berigan  2 , Federica Madia  2
Affiliations

Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus

Vincent J Cogliano et al. Lancet Oncol. 2025 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

All Working Group Members declare no competing interests

Declaration of interests

ABAB reports research funding from a pharmaceutical company that markets voriconazole and tacrolimus

Declaration of interests

All Secretariat declare no competing interests

For IARC declarations of interests see https://monographs.iarc.who.int/wp-content/uploads/2024/11/Vol137_Short_List_of_Participants-website.pdf

References

    1. International Agency for Research on Cancer. Volume 137: Hydrochlorothiazide, voriconazole, and tacrolimus. Lyon, France; Nov 5–12, 2024. IARC Monogr Identif Carcinog Hazards Hum (in press).
    1. Pedersen SA, Gaist D, Schmidt SAJ, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78: 673–81.e9. - PubMed
    1. Eworuke E, Haug N, Bradley M, et al. Risk of nonmelanoma skin cancer in association with use of hydrochlorothiazide-containing products in the United States. JNCI Cancer Spectr 2021; 5: pkab009. - PMC - PubMed
    1. Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282: 322–331. - PubMed
    1. National Toxicology Program. Toxicology and carcinogenesis studies of hydrochlorothiazide (CAS No. 58-93-5) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Program Tech Rep Ser 1989; 357: 1–194. - PubMed

LinkOut - more resources